Skip to main content
. 2016 Sep 6;34(32):3921–3930. doi: 10.1200/JCO.2016.66.9648

Fig 3.

Fig 3.

Percentage of patient-reported outcome responders for European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) domain at cycles 3, 6, 12, and 18. A responder was defined as having a (A) ≥ 5-point improvement or (B) ≥ 15-point improvement from baseline for QLQ-C30 GHS/QoL. Missing data were assumed to have not reached the required improvement. GHS/QoL, Global Health Status/Quality of Life domain; KRd, carfilzomib, lenalidomide, and dexamethasone; Rd, lenalidomide and dexamethasone.